{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:32:35Z","timestamp":1755221555895,"version":"3.43.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["M21013"],"award-info":[{"award-number":["M21013"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFA0900804"],"award-info":[{"award-number":["2018YFA0900804"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970875","82271869"],"award-info":[{"award-number":["31970875","82271869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ijbiomac.2022.09.180","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T12:28:43Z","timestamp":1663763323000},"page":"661-670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"PA","title":["A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan"],"prefix":"10.1016","volume":"222","author":[{"given":"Yunxia","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weili","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinming","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0005","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V'kovski","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0010","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-CoV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0015","doi-asserted-by":"crossref","DOI":"10.2174\/1871526520666201006163641","article-title":"COVID-19, SARS-CoV-2, origin, transmission and treatment aspects, a brief review","volume":"21","author":"Nawaz","year":"2021","journal-title":"Infect. Disord. Drug Targets"},{"author":"WHO","key":"10.1016\/j.ijbiomac.2022.09.180_bb0020"},{"issue":"6572","key":"10.1016\/j.ijbiomac.2022.09.180_bb0025","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1126\/science.acx9738","article-title":"Where did 'weird' omicron come from?","volume":"374","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s44197-022-00032-w","article-title":"The emergence of the omicron (B.1.1.529) SARS-CoV-2 variant: what is the impact on the continued pandemic?","volume":"12","author":"Al-Tawfiq","year":"2022","journal-title":"J. Epidemiol. Glob.Health"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0035","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1080\/21655979.2022.2031417","article-title":"COVID-19 in southeast Asia: current status and perspectives","volume":"13","author":"Chu","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0040","doi-asserted-by":"crossref","DOI":"10.4110\/in.2021.21.e32","article-title":"SARS-CoV-2 delta (B.1.617.2) variant: a unique T478K mutation in receptor binding motif (RBM) of spike gene","volume":"21","author":"Jhun","year":"2021","journal-title":"Immune Netw."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108634","article-title":"COVID-19: a review of therapeutic strategies and vaccine candidates","volume":"222","author":"Izda","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0050","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cell.2020.06.008","article-title":"Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2","volume":"182","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0065","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0070","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1126\/science.abc6284","article-title":"DNA vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0075","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0080","article-title":"SARS-CoV-2 RBD neutralizing antibody induction is enhanced by particulate vaccination","volume":"32","author":"Huang","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0085","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","article-title":"Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial","volume":"21","author":"Xia","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0090","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","article-title":"Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine","volume":"383","author":"Keech","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0095","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0100","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","article-title":"Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review","volume":"28","author":"Fiolet","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0105","doi-asserted-by":"crossref","first-page":"eabd1525","DOI":"10.1126\/scitranslmed.abd1525","article-title":"Development and deployment of COVID-19 vaccines for those most vulnerable","volume":"13","author":"Koff","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.585354","article-title":"A review of the progress and challenges of developing a vaccine for COVID-19","volume":"11","author":"Sharma","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0115","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 COVID-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0120","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jobm.202000537","article-title":"SARS-CoV-2, the pandemic coronavirus: molecular and structural insights","volume":"61","author":"Kadam","year":"2021","journal-title":"J. Basic Microbiol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmb.2020.11.024","article-title":"Structural insights into SARS-CoV-2 proteins","volume":"433","author":"Arya","year":"2021","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0130","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0135","doi-asserted-by":"crossref","first-page":"6121","DOI":"10.1038\/s41467-020-19819-1","article-title":"Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform","volume":"11","author":"Chiuppesi","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0140","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41541-021-00393-6","article-title":"Scientific rationale for dev eloping potent RBD-based vaccines targeting COVID-19","volume":"6","author":"Kleanthous","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0145","doi-asserted-by":"crossref","first-page":"21779","DOI":"10.1038\/s41598-020-78711-6","article-title":"Structural and functional comparison of SARS-CoV-2 spike receptor binding domain produced in Pichia pastoris and mammalian cells","volume":"10","author":"Arbeitman","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0155","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/21645515.2020.1740560","article-title":"Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19","volume":"16","author":"Chen","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0160","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3390\/diagnostics11020271","article-title":"Serological test to determine exposure to SARS-CoV-2: ELISA based on the receptor-binding domain of the spike protein (S-RBD (N318\u2013V510)) expressed in Escherichia coli","volume":"11","author":"Marquez-Ipina","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0165","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/elsc.202000106","article-title":"Purification and characterization of the receptor-binding domain of SARS-CoV-2 spike protein from Escherichia coli","volume":"21","author":"He","year":"2021","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbrc.2021.04.056","article-title":"Production in Escherichia coli of recombinant COVID-19 spike protein fragments fused to CRM197","volume":"558","author":"Bellone","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0175","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S1473-3099(21)00127-4","article-title":"Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials","volume":"21","author":"Yang","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.addr.2020.12.008","article-title":"Non-viral COVID-19 vaccine delivery systems","volume":"169","author":"Park","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0185","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1172\/JCI81083","article-title":"Beyond antigens and adjuvants: formulating future vaccines","volume":"126","author":"Moyer","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0190","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jtemb.2019.09.010","article-title":"An aluminium adjuvant in a vaccine is an acute exposure to aluminium","volume":"57","author":"Exley","year":"2020","journal-title":"J. Trace Elem. Med. Biol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0195","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14760584.6.5.723","article-title":"GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives","volume":"6","author":"Garcon","year":"2007","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0200","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.172","article-title":"Bacterial flagellin-a potent immunomodulatory agent","volume":"49","author":"Hajam","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0205","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.vaccine.2018.12.009","article-title":"Recombinant flagellins with deletions in domains D1, D2, and D3: characterization as novel immunoadjuvants","volume":"37","author":"Biedma","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0210","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.4049\/jimmunol.181.3.2036","article-title":"Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity","volume":"181","author":"Nempont","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0215","doi-asserted-by":"crossref","DOI":"10.1177\/0394632017742504","article-title":"Mannosylated T\/Tn with Freund's adjuvant induces cellular immunity","volume":"31","author":"Son","year":"2018","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0220","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1021\/acs.bioconjchem.0c00700","article-title":"Conjugation of hemoglobin and mannan markedly improves the immunogenicity of domain III of the Zika virus E protein: structural and immunological study","volume":"32","author":"Qi","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0225","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ijbiomac.2021.08.177","article-title":"Conjugation of Zika virus EDIII with CRM197, 8-arm PEG and mannan for development of an effective Zika virus vaccine","volume":"190","author":"He","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0230","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1021\/acs.bioconjchem.6b00116","article-title":"A potent antigen-adjuvant delivery system by conjugation of mycobacterium tuberculosis Ag85B-HspX fusion protein with arabinogalactan-poly(I:C) conjugate","volume":"27","author":"Huang","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0235","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2007.07.037","article-title":"Characterization and immunogenicity of meningococcal group C conjugate vaccine prepared using hydrazide-activated tetanus toxoid","volume":"25","author":"Silverira","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.ijbiomac.2022.09.180_bb0240","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","article-title":"Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads","volume":"36","author":"Masters","year":"2018","journal-title":"Investig. New Drugs"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813022021122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T01:38:31Z","timestamp":1754703511000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813022021122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":48,"alternative-id":["S0141813022021122"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.180","relation":{},"ISSN":["0141-8130"],"issn-type":[{"type":"print","value":"0141-8130"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A SARS-CoV-2 vaccine based on conjugation of SARS-CoV-2 RBD with IC28 peptide and mannan","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.09.180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}